ACVR2A
ENSG00000121989
Target class
Kinase
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Other names
- ACTRII
- Target name
- ACVR2A
- Gene name
- Activin A receptor type 2A
- Gene symbol
- ACVR2A
- Previous gene symbols
- ACVR2
- Protein name
- Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA)
- Gene biotype
- Protein coding
- Gene family
- Type 2 receptor serine/threonine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 26.05
- Tissue specificity (Gini)
- 0.367
- Tissue specificity (tau)
- 0.738
- KEGG gene identifiers
- hsa:92
- Protein interaction confidence
- 0.938898
- Protein interaction partners
- 49
- R-HSA-1181150
- R-HSA-1433617
- R-HSA-1502540
- R-HSA-201451
- R-HSA-9839406
- End position
- 147930826
- Start position
- 147844378
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein .
- Cytosol
- Tissue specificity (tau)
- 0.737899
- Expression inequality (Gini)
- 0.367091
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)
- 26.05
- Skin - Sun Exposed (Lower leg)
- 26.04
- Vagina
- 13.49
- Bladder
- 13.28
- Brain - Cerebellar Hemisphere
- 13.08
Expression in transcripts per million
- Skin - Not Sun Exposed (Suprapubic)26.05
- Skin - Sun Exposed (Lower leg)26.04
- Vagina13.49
- Bladder13.28
- Brain - Cerebellar Hemisphere13.08
- Nerve - Tibial12.73
- Brain - Cerebellum11.69
- Esophagus - Muscularis10.99
- Minor Salivary Gland10.94
- Adipose - Subcutaneous10.7
- Cervix - Ectocervix10.56
- Uterus10.21
- Esophagus - Gastroesophageal Junction9.87
- Testis9.54
- Breast - Mammary Tissue9.52
- Cervix - Endocervix9.23
- Thyroid8.72
- Colon - Sigmoid8.65
- Fallopian Tube8.55
- Esophagus - Mucosa8.49
- Prostate8.42
- Ovary8.26
- Artery - Tibial7.99
- Lung7.65
- Adipose - Visceral (Omentum)7.55
And 29 more, listed on the interactive page.
- GO:0001649
- GO:0001934
- GO:0007178
- GO:0030501
- GO:0030509
- GO:0032924
- GO:0032927
- GO:0045648
- GO:0045669
- GO:0045944
- GO:0060391
- GO:0071773
- GO:0005737
- GO:0005886
- GO:0034673
- GO:0043235
- GO:0004674
- GO:0004675
- GO:0005515
- GO:0015026
- GO:0016361
- GO:0016362
- GO:0017002
- GO:0048185
Related records
Trials (35)
- A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
- A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults
- A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
- A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
- A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
- An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
- Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult
- BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement
- Bone Morphogenetic Protein-2 In Grade II Furcation Defects.
- BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
- Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
- Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
- Dose Range Finding Study of Bimagrumab in Sarcopenia
- Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
- Effect of Recombinant Human Bone Morphogenetic Protein-2 With an Absorbable Collagen Sponge on Stability of Dental Implant: (Split Mouth Randomized Clinical Trial Study.
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
- Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
- Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Drugs (3)
- Bimagrumab
- Dibotermin alfa Activin receptor type-2A agonist
- Eptotermin alfa